Trump’s Bold Move — MAJOR MEDICARE Drug Shift

Medicare card glasses pen money on wooden table

Medicare seniors are about to get access to blockbuster weight-loss drugs for $50 a month — but only after the Trump administration’s original plan collapsed when private insurers refused to participate, forcing Washington to foot the entire bill itself.

Quick Take

Trump negotiated deals with Eli Lilly and Novo Nordisk cutting GLP-1 drug prices from over $1,000 to $245 per month for Medicare and Medicaid patients.
The BALANCE pilot program — designed to test Medicare coverage of weight-loss drugs through private insurers — was canceled in April 2026 after insurers refused to sign on.
CMS pivoted to a government-funded “GLP-1 Bridge” program launching July 2026, capping seniors’ out-of-pocket costs at $50 per month through 2027.
Medicare currently spends $27.5 billion annually on GLP-1 drugs, and absorbing full obesity coverage costs without insurer risk-sharing raises serious long-term budget questions.

A Pricing Win Built on a Legal Workaround

Federal law has prohibited Medicare from covering weight-loss drugs since the 2003 Medicare Modernization Act, restricting GLP-1 medications like Wegovy and Zepbound to FDA-approved uses such as type 2 diabetes and cardiovascular risk reduction. The Trump administration bypassed this statutory barrier using CMS demonstration authority — a regulatory tool that allows the government to test new payment models outside existing law. Without this workaround, tens of millions of obese seniors would remain legally locked out of coverage regardless of price.

In November 2025, the White House announced most-favored-nation pricing deals with Eli Lilly and Novo Nordisk, setting Medicare and Medicaid prices at $245 per month for Ozempic, Wegovy, Mounjaro, and Zepbound. The administration framed this as cutting prices to less than half of what the Biden administration had proposed. In exchange for the discounts, manufacturers gained access to Medicare’s 65 million beneficiaries — a market expansion that offsets reduced per-unit revenue through dramatically higher volume.

When Insurers Said No, Washington Said Yes

CMS designed the BALANCE model — Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth — as a five-year pilot requiring private Medicare Part D insurers to cover GLP-1s for obesity under specific BMI thresholds. Eligibility required a BMI of 27 or higher with comorbidities like prediabetes or cardiovascular disease, or a BMI of 30 to 35 with conditions including hypertension or chronic kidney disease. Participation by insurers covering at least 80 percent of eligible beneficiaries was required for the program to function.

The April 20, 2026, insurer signup deadline passed without sufficient participation. Health insurers, represented by the trade group America’s Health Insurance Plans, cited financial risk as the primary obstacle — they would bear costs without adequate reimbursement guarantees. CMS canceled BALANCE the following day and announced the GLP-1 Bridge as a replacement. Under the Bridge, Medicare directly funds the program at the $245 net manufacturer price, with seniors paying a $50 monthly copay that does not count toward Part D deductibles or out-of-pocket maximums.

What Seniors Actually Get — and What It Costs Everyone Else

The GLP-1 Bridge launches in July 2026 and runs through 2027, operating entirely outside standard Medicare Part D. Eligible seniors access drugs through prior authorization, and the program is explicitly framed as a transitional measure while CMS collects data to potentially revive a permanent BALANCE model. AHIP called the Bridge a “logical step” toward sustainable coverage — notably more supportive once insurers were no longer on the financial hook.

The fiscal picture deserves scrutiny. Medicare already recorded $27.5 billion in gross GLP-1 spending in 2024 — before obesity was even a covered indication. Adding millions of newly eligible obese seniors to a fully government-funded program, with no insurer risk-sharing, significantly expands taxpayer exposure. Supporters argue that reducing obesity-related conditions like cardiovascular disease and diabetes could generate long-term Medicare savings. Critics note that argument remains unproven, and the Bridge’s one-year data window is a thin basis for a potentially permanent entitlement expansion. Whether this is smart preventive investment or another federal program that grows beyond its original scope is a question both conservatives and liberals concerned about government spending have every right to ask.